Myeloma Minute: Is This the End of Bacon?
The Bad and the Good About Food, Cancer, and Longevity
In his blog this week, IMF Chairman Dr. Brian Durie discusses the media frenzy surrounding The World Health Organization (WHO) study that proposed red and processed meats could be linked to cancer. The WHO and its linked research group, the International Agency for Research on Cancer (IARC) classified bacon and hot dogs as “human carcinogens (Group 1).” That designation means they are causing cancer in the same way that tobacco and asbestos are classified as cancer-causing agents. There is more to this story than just the headlines however, and Dr. Durie explains more about what this study means HERE.
IMF Scores Support in Takeda Oncology's '3 Points for Patients' Campaign with NBA's Boston Celtics
The IMF is thrilled to announce their partnership with Takeda Oncology and their new campaign “3 Points for Patients,” with the Boston Celtics, which launched today. Each time the 17-time champion Boston Celtics sinks a 3-point basket during the regular NBA season, Takeda Oncology will make a donation to the IMF. With the high-scoring Celtics’ track record, that could result in an additional $25,000 to support IMF’s myeloma research and patient education programs. Read the full story, HERE.
Register Now for the Next Living Well with Myeloma Teleconference on November 19
Don’t miss the next teleconference in the Living Well with Myeloma series happening Thursday, November 19. IMF Chairman Dr. Brian Durie will present “Myeloma 101: Updates on Treatment & Pain Management” during this informative teleconference, and will shed light on the most up-to-date therapies for myeloma patients. The 60-minute teleconference begins at 4 pm PT/7 pm ET and is not to be missed! To register, please click HERE.
Register for the IMF Advocacy Team's Webinar on Understanding Clinical Pathways
Please join the IMF Advocacy team on Wednesday, November 11 from 7:00 – 7:30 PM EST, for a special presentation on Clinical Pathways. Pathways are a mechanism used by insurers to make health care costs more predictable by prescribing a course of treatment in which the type and timing of specific therapies are pre-determined. The presentation will go over how pathways are developed, so that you can make more informed decisions about your care. It will also cover how to talk to your physician about how these pathways are structured within their practices and whether they have placed you on a particular pathway. To register, please click HERE. We hope to see you there!
